![]() ![]() | Vanderplanck, C., Tassin, A., Ansseau, E., Charron, S., Wauters, A., Lancelot, C., Vancutsem, K., Laoudj Chevinesse, D., Belayew, A., & Coppée, F. (12 January 2018). 'Overexpression of the double homeodomain protein DUX4c interferes with myofibrillogenesis and induces clustering of myonuclei'. Skeletal Muscle, 8 (2). doi:10.1186/s13395-017-0148-4 ![]() |
![]() ![]() | Ansseau, E., Vanderplanck, C., Wauters, A., Harper, S. Q., Coppée, F., & Belayew, A. (03 March 2017). Oligonucleotides Used to Target the DUX4 mRNA as Therapeutic Approaches in FaciosScapuloHumeral Muscular Dystrophy (FSHD). Genes, 8 (3), 93. doi:10.3390/genes8030093 ![]() |
![]() ![]() | Ansseau, E., Lancelot, C., Wauters, A., Vanderplanck, C., Belayew, A., & Coppée, F. (10 November 2016). Transcription factors DUX4 and DUX4c associate with mRNP granules in the cytoplasm of fusing myoblasts: a new function in translation regulation? [Poster presentation]. FSH Society, Boston, United States - Massachusetts. |
De La Kethulle De Ryove, L., Ansseau, E., Nachtegael, C., Pieters, K., Vanderplanck, C., Geens, M., Sermon, K., Wilton, S., Coppée, F., Lagneaux, L., & Belayew, A. (14 March 2016). The Role of D4Z4-Encoded Proteins in the Osteogenic Differentiation of Mesenchymal Stromal Cells Isolated from Bone Marrow [Poster presentation]. 5th International Congress of Myology, Lyon, France. |
De La Kethulle De Ryhove, L., Ansseau, E., Nachtegael, C., Pieters, K., Vanderplanck, C., Geens, M., Sermon, K., Wilton D., S., Coppée, F., Lagneaux, L., & Belayew, A. (06 October 2015). The Role of D4Z4-Encoded Proteins in the Osteogenic Differentiation of Mesenchymal Stromal Cells Isolated from Bone Marrow [Paper presentation]. FSH Society, Boston, United States - Massachusetts. |
Vanderplanck, C., Tassin, A., Ansseau, E., Lancelot, C., Derenne, A., Conotte, S., Dudome, V., Leroy, B., Wilton D., S., Laoudj-Chenivesse, D., Wattiez, R., Legrand, A., Belayew, A., & Coppée, F. (2015). Antisense strategies targeting DUX4 and DUX4c for the treatment of Facioscapulohumeral muscular dystrophy [Paper presentation]. International World Muscle Society congress, Brighton, United Kingdom. |
De La Kethulle De Ryhove, L., Ansseau, E., Nachtegael, C., Pieters, K., Vanderplanck, C., Geens, M., Sermon, K., Wilton D., S., Coppée, F., Lagneaux, L., & Belayew, A. (20 July 2015). The Role of D4Z4-Encoded Proteins in the Osteogenic Differentiation of Mesenchymal Stromal Cells Isolated from Bone Marrow. Stem Cells and Development, 24 (22), 2674-86. doi:10.1089/scd.2014.0575 ![]() |
Vanderplanck, C., Tassin, A., Ansseau, E., Lancelot, C., Derenne, A., Conotte, S., Dudome, V., Leroy, B., Wilton D., S., Laoudj-Chenivesse, D., Wattiez, R., Legrand, A., Belayew, A., & Coppée, F. (22 May 2015). Antisense strategies targeting DUX4 and DUX4c for the treatment of Facioscapulohumeral muscular dystrophy [Poster presentation]. Journée UMHAP from lab to bedside, Mons, Belgium. |
Vanderplanck, C., Tassin, A., Ansseau, E., Lancelot, C., Derenne, A., Conotte, S., Dudome, V., Leroy, B., Wilton D., S., Laoudj-Chenivesse, D., Wattiez, R., Legrand, A., Belayew, A., & Coppée, F. (17 April 2015). Antisense strategies targeting DUX4 and DUX4c for the treatment of facioscapulohumeral muscular dystrophy (FSHD [Poster presentation]. Novel Therapies for monogennic diseases, Paris, France. |
Vanderplanck, C., Tassin, A., Ansseau, E., Lancelot, C., Derenne, A., Conotte, S., Dudome, V., Leroy, B., Wilton D., S., Laoudj-Chenivesse, D., Wattiez, R., Legrand, A., Belayew, A., & Coppée, F. (15 April 2015). Antisense strategies targeting DUX4 and DUX4c for the treatment of Facioscapulohumeral muscular dystrophy [Poster presentation]. symposium de thérapie génique du Collège de France, Paris, France. |
De La Kethulle De Ryhove, L., Ansseau, E., Nachtegael, C., Pieters, K., Vanderplanck, C., Geens, M., Sermon, K., Wilton D., S., Coppée, F., Lagneaux, L., & Belayew, A. (11 February 2015). The Role of D4Z4-Encoded Proteins in the Osteogenic Differentiation of Mesenchymal Stromal Cells Isolated from Bone Marrow [Poster presentation]. Télévie's Research Seminar, ULB-Erasme, Belgium. |
![]() ![]() | Charron, S., Vancutsem, K., Vanderplanck, C., Lancelot, C., Carnac, G., Laoudj-Chenivesse, D., Belayew, A., & Coppée, F. (17 October 2014). WNT pathway alterations in FSHD [Poster presentation]. FSH Society international research consortium and research planning meeting, San Diego, United States - California. |
Charron, S., Vancutsem, K., Vanderplanck, C., Lancelot, C., Laoudj-Chenivesse, D., Belayew, A., & Coppée, F. (14 May 2014). WNT pathway alterations in FSHD [Poster presentation]. EMBO Conference : Molecular Biology of Muscle Development and Regeneration, Acaya-Lecce, Italy. |
![]() ![]() | Vanderplanck, C., Tassin, A., Lancelot, C., Ansseau, E., Nonclercq, D., Delrée, P., Laoudj-Chenivesse, D., Belayew, A., & Coppée, F. (27 November 2013). DUX4c, a DUX4-homologue, causes the FSHD disorganized myotube phenotype: an additional target for therapeutic strategies [Paper presentation]. Colloque Myogenèse XVI, Montpellier, France. |
![]() ![]() | Tassin, A., Vanderplanck, C., Ansseau, E., Derenne, A., Coppée, F., & Belayew, A. (24 May 2013). Different approaches to evaluate antisense strategies against the causal gene of the FSHD myopathy [Poster presentation]. Journée de l'Institut de recherche en sciences et technologies de la santé, Mons, Belgium. |
Ansseau, E., Vanderplanck, C., Wallace, L. M., Tassin, A., Domire, J. S., Guckes, S. M., Yip, C., Laoudj-Chenivesse, D., Coppée, F., Wilton D., S., Harper, S. Q., & Belayew, A. (22 April 2013). Evaluation of new antisense oligomers targeting the DUX4 mRNA as a therapeutic strategy for FSHD [Paper presentation]. MDA Scientific Conference, Washington DC, United States - District of Columbia. |
![]() ![]() | Tassin, A., Laoudj-Chenivesse, D., Vanderplanck, C., Barro, M., Charron, S., Ansseau, E., Chen, Y.-W., Mercier, J., Coppée, F., & Belayew, A. (01 January 2013). DUX4 expression in FSHD muscle cells: how could such a rare protein cause a myopathy? Journal of Cellular and Molecular Medicine, 17 (1), 1-15. doi:10.1111/j.1582-4934.2012.01647.x ![]() |
![]() ![]() | Tassin, A., Leroy, B., Laoudj-Chenivesse, D., Wauters, A., Vanderplanck, C., Le Bihan, M.-C., Coppée, F., Wattiez, R., & Belayew, A. (18 December 2012). FSHD Myotubes with Different Phenotypes Exhibit Distinct Proteomes. PLoS ONE, 7 (12), 51865. doi:10.1371/journal.pone.0051865 ![]() |
![]() ![]() | Tassin, A., Vanderplanck, C., Leroy, B., Charron, S., Ansseau, E., Wauters, A., Laoudj-Chenivesse, D., Wattiez, R., Belayew, A., & Coppée, F. (07 November 2012). Investigations on the FSHD disorganized myotube phenotype [Poster presentation]. FSH Society International Reasearch Consortium Meeting, San Francisco, United States. |
Ansseau, E., Vanderplanck, C., Wallace, L. M., Tassin, A., Domire, J. S., Guckes, S. M., Yip, C., Laoudj-Chenivesse, D., Coppée, F., Wilton D., S., Harper, S. Q., & Belayew, A. (06 November 2012). Evaluation of new antisense oligomers targeting the DUX4 mRNA as a therapeutic strategy for FSHD [Paper presentation]. FSH Society International Reasearch Consortium Meeting, San Francisco, United States. |
Charron, S., Vanderplanck, C., Vancutsem, K., Laoudj-Chenivesse, D., Belayew, A., & Coppée, F. (25 September 2012). Facioscapulohumeral dystrophy: focus on the WNT perturbation [Poster presentation]. EMBO Meeting, Nice, France. |
![]() ![]() | Charron, S., Vanderplanck, C., Laoudj-Chenivesse, D., Belayew, A., & Coppée, F. (07 November 2011). Perturbation of the WNT signaling pathway in FSHD [Paper presentation]. FSH Society (FSHD) 2011 International Research Consortium and Researchplanning meetings, Boston, United States - Massachusetts. |
Vanderplanck, C., Ansseau, E., Coppée, F., Belayew, A., & Wilton D., S. (01 September 2010). Agents useful in treating Facioscapulohumeral muscular dystrophy. |
Tassin, A., Coppée, F., Leroy, B., Sauvage, S., Preillon, J., Erculisse, V., Charron, S., Vanderplanck, C., Barro, M., Vander Elst, L., Muller, R., Laoudj-Chenivesse, D., Colet, J.-M., Wattiez, R., & Belayew, A. (09 November 2009). Investigations on the molecular mechanism of a muscular dystrophy (FSHD) by proteomic and metabonomic analyses of primary myoblast cultures [Paper presentation]. FSH Society International Research Consortium and Research Planning Meetings, Boston, United States - Massachusetts. ![]() |
Charron, S., Vanderplanck, C., Belayew, A., & Coppée, F. (17 October 2009). WNT and FOXO signaling pathways in FSHD [Poster presentation]. Protein modifications in development and diseases, Liège, Belgium. |
Tassin, A., Coppée, F., Leroy, B., Erculisse, V., Sauvage, S., Charron, S., Vanderplanck, C., Barro, M., Vander Elst, L., Muller, R., Laoudj-Chenivesse, D., Colet, J.-M., Wattiez, R., & Belayew, A. (27 July 2009). Investigations on the molecular mechanism of a muscular dystrophy (FSHD) by proteomic and metabonomic analyses of primary myoblast cultures [Paper presentation]. International Symposium Signal transduction and disease, Aachen, Germany. ![]() |
Tassin, A., Vanderplanck, C., Ansseau, E., Marcowyzc, A., Barro, M., Laoudj-Chenivesse, D., Belayew, A., & Coppée, F. (26 May 2008). Studies on the expression and function of DUX4c, a gene located close to the FSHD locus [Poster presentation]. 3ème Congrès International de Myologie, Marseille, France. |
Tassin, A., Ansseau, E., Vanderplanck, C., Cloet, S., Barro, M., Laoudj-Chenivesse, D., Chen, Y.-W., Belayew, A., & Coppée, F. (21 January 2008). DUX4 and DUX4c activate different pathways in Facioscapulohumeral dystrophy [Paper presentation]. Colloque « Myogenese IX », Institut de Myologie, Paris, France. ![]() |
Ansseau, E., Tassin, A., Vanderplanck, C., Cloet, S., Barro, M., Laoudj-Chenivesse, D., Chen, Y.-W., Belayew, A., & Coppée, F. (04 November 2007). Further studies on the DUX4, DUX4c and PITX1 genes in FSHD [Paper presentation]. FSHD international Workshop meeting, San Diego, United States - California. |